NCT06178822 Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
| NCT ID | NCT06178822 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC) |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,300 participants |
| Start Date | 2022-10-25 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,300 participants in total. It began in 2022-10-25 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Objectives: 1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection. 2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis. 3. To determine the long term cognitive and physical sequelae of sepsis after admission.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or higher * Presentation at the Emergency Department (ED) * Clinical suspicion of infection or earlier confirmed infection * Modified Early Warning Score (MEWS) of 2 or higher Exclusion Criteria: * No informed consent given
Contact & Investigator
Willem Joost Wiersinga, MD, PhD
PRINCIPAL INVESTIGATOR
Amsterdam UMC, location AMC
Frequently Asked Questions
Who can join the NCT06178822 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06178822 currently recruiting?
Yes, NCT06178822 is actively recruiting participants. Contact the research team at biosep@amsterdamumc.nl for enrollment information.
Where is the NCT06178822 trial being conducted?
This trial is being conducted at Almere Stad, Netherlands, Amsterdam, Netherlands, Amsterdam, Netherlands.
Who is sponsoring the NCT06178822 clinical trial?
NCT06178822 is sponsored by Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC). The principal investigator is Willem Joost Wiersinga, MD, PhD at Amsterdam UMC, location AMC. The trial plans to enroll 3,300 participants.